ONABOTULINUMTOXINA IS WELL TOLERATED IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: LONG-TERM COMPEL ANALYSIS BY TREATMENT CYCLE

被引：0
|
作者：
Winner, Paul K. [1 ]
Blumenfeld, Andrew M. [2 ]
Eross, Eric J. [3 ]
Orejudos, Amelia [4 ]
Adams, Aubrey Manack [4 ]
Brin, Mitchell F. [4 ,5 ]
机构：
[1] Palm Beach Headache Ctr, Premiere Res Inst Palm Beach Neurol, W Palm Beach, FL USA
[2] Headache Ctr Southern Calif, Neurol Ctr, Carlsbad, CA 92011 USA
[3] Phoenix Headache Inst, Scottsdale, AZ USA
[4] Allergan Plc, Irvine, CA USA
[5] Univ Calif Irvine, Irvine, CA USA
来源：
TOXICON | 2018年 / 156卷
关键词：
Adverse events; Chronic migraine; COMPEL; Concomitant medication; OnabotulinumtoxinA; Safety;
D O I：
10.1016/j.toxicon.2018.11.274
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
264
引用
收藏
页码：S114 / S114
页数：1
相关论文
共 50 条
  • [31] Efficacy, tolerability, and safety of onabotulinumtoxinA treatment for chronic migraine in patients with acute medication overuse: analysis of the PREEMPT and COMPEL trials
    Agosti, R.
    Straube, A.
    Diener, H. C.
    Freeman, M.
    Pascual Gomez, J.
    Seminerio, M.
    Delahaye, L.
    Stark, R. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [32] Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
    Blumenfeld, Andrew
    Ettrup, Anders
    Hirman, Joe
    Ebert, Bjarke
    Cady, Roger
    BMC NEUROLOGY, 2022, 22 (01)
  • [33] Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
    Andrew Blumenfeld
    Anders Ettrup
    Joe Hirman
    Bjarke Ebert
    Roger Cady
    BMC Neurology, 22
  • [34] Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
    Blumenfeld, A.
    Ettrup, A.
    Hirman, J.
    Ebert, B.
    Cady, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 418 - 418
  • [35] Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis
    Young, William B.
    Lopez, J. Ivan
    Rothrock, John F.
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    CEPHALALGIA, 2017, 37 : 100 - 101
  • [36] Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis
    Young, William B.
    Rothrock, John F.
    Lopez, J. Ivan
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    NEUROLOGY, 2018, 90
  • [37] Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life
    Tassorelli, Cristina
    Tedeschi, Gioacchino
    Sarchielli, P.
    Pini, Luigi Alberto
    Grazzi, Licia
    Geppetti, Pierangelo
    De Tommaso, Marina
    Aguggia, Marco
    Cortelli, P.
    Martelletti, Paolo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2018, 18 (02) : 167 - 176
  • [38] Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
    Cernuda-Morollon, Eva
    Ramon, Cesar
    Larrosa, Davinia
    Alvarez, Rocio
    Riesco, Nuria
    Pascual, Julio
    CEPHALALGIA, 2015, 35 (10) : 864 - 868
  • [39] Cost-Effectiveness of Initial Prophylactic Treatment of Chronic Migraine: Oral Medications versus OnabotulinumtoxinA
    Kelley, Kristin
    Schoenbrunner, Anna
    Murphy, James
    NEUROLOGY, 2016, 86
  • [40] EFFICACY AND SAFETY OF ONABOTULINUMTOXINA IN AN OPEN-LABEL STUDY FOR THE PROPHYLACTIC TREATMENT OF CHRONIC MIGRAINE IN ADULT PATIENTS: COMPEL
    Blumenfeld, A.
    Stark, R.
    Adams, A. Manack
    Orejudos, A.
    Aurora, S.
    CEPHALALGIA, 2016, 36 : 27 - 28
12345